Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

Overview

The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus.

Full Title of Study: “Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2011

Detailed Description

Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic and increasing the risk for developing nonalcoholic fatty liver disease (NAFLD). NAFLD is a group of diseases with too much fat in liver in the absence of excess alcohol consumption. NAFLD encompasses a histological spectrum ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. NAFLD is estimated to affect 25% of the worldwide population[1] and 15.35% of adults in shanghai urban area[2]. Epidemiological data showed that the fatty liver may predict, independent of other factors, the metabolic syndrome, type 2 diabetes, and cardiovascular disease. Therefore, we may prevent those diseases by treating NAFLD.Life style intervention including activity and reducing energy intake is recommended by health care providers for optimal health and is the most common prescribed therapy for individuals diagnosed with NAFLD. TZDs are oral glucose-lowering medications used to treat type 2 diabetes that enhance insulin sensitivity. The strong relationship between insulin resistance and NAFLD suggests that insulin sensitizing therapies such as TZDs might be beneficial in the prevention or improvement in NAFLD.TZDs bind to the peroxisome proliferator-activated receptors (PPARs), in part, by facilitating enhanced TG storage by adipocytes, suppressing the ectopic storage of lipids into liver and skeletal muscle. In addition, TZDs appear to have anti-inflammatory properties, inhibiting adipocyte gene expression and reducing circulating levels of TNFα[3] and resistin[4], and increasing adiponectin concentrations[5]. Some researches demonstrated that pioglitazone(a TZD) significantly reduced liver fat content of NAFLD, and ameliorated biological parameters and liver histology of NASH[6]. However, there have not been similar data of treating chinese NAFLD with pioglitazone. Berberine (BBR), a compound isolated from a Chinese herb was identified by Weijia [7] as a new cholesterol-lowering drug with a mechanism different from that of statin drugs. BBR elevates LDL receptor(LDLR) expression through a post-transcriptional mechanism that stabilizes the LDLR-mRNA. Considering the close relationship between NAFLD and lipid metabolism, we assume that BBR may be effective for NAFLD by improving lipid metabolism. In order to evaluate these hypotheses, we plan to treat a group of NAFLD patients with impaired glucose regulation (IGR) or T2DM with pioglitazone or BBR in a randomized, open, controlled trial for 16 weeks.

Interventions

  • Behavioral: Life style intervention
    • calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate
  • Drug: pioglitazone
    • pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
  • Drug: berberine
    • berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks

Arms, Groups and Cohorts

  • Experimental: Lifestyle intervention
    • Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
  • Experimental: Life style intervention, pioglitazone
    • Life style intervention with pioglitazone 15mg qd for 16 weeks
  • Experimental: Life style intervention, berberine
    • Life style intervention with berberine 0.5g tid for 16 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Improved metabolic parameters(glucose, lipid, liver enzymes, etc.)
    • Time Frame: 16 weeks
    • improvement of the metabolic parameters, including serum glucose of OGTT, fasting glucose,2 hour glucose,area under the glucose curve and HbA1c,lipid profile(TC、TG、HDL-c、LDL-c、ApoA、ApoB、ApoE and Lpa),liver enzymes(ALT,AST,ALP,γ-GT).

Secondary Measures

  • liver fat content
    • Time Frame: 16 weeks
    • improvement of liver fat content by 1H NMR spectroscopy
  • serum insulin
    • Time Frame: 16 weeks
    • improvement of serum insulin including fasting insulin,2 hour insulin and area under insulin curve.
  • the ratio of withdrawing because of inefficiency
    • Time Frame: 16 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Patients must have an age range between 18 to 65 years (inclusive). 2. Patients with fatty liver confirmed by ultrasound. 3. Patients must meet the criteria for impaired glucose regulation or type 2 diabetes mellitus (FPG ≥ 5.6 mmol/L and/or a two hour glucose value ≥ 7.8 mmol/L). 4. Course of diabetic mellitus no more than 1 years 5. Diabetic patients have not received anti-diabetic drugs, including insulin, biguanides, sulfonylureas, thiazolidinediones, Alpha-glucosidase inhibitors, or glinides for 4 weeks before the time of enrollment 6. Patients have not received lipid-regulating drugs (statins, fibrates)for 4 weeks before the time of enrollment 7. Blood pressure < 160/100 mmHg,after receiving lifestyle therapy and effective anti-hypertensive drugs. 8. Patients must stopped other drugs medications for four weeks prior to entering the treatment period, such as: silybin, ursodeoxycholic acid, Polyene Phosphatidylcholine, vitamin E, some herbs with effect of regulating lipid and protecting liver function, etc. 9. Liver fat content(LFC) assessed by 1H MRS ≥ 13%(LFC was calculated by dividing the integral of the methylene groups in fatty acid chains of the hepatic triglycerides by the sum of methylene groups and water). Exclusion Criteria:

1. Any causes of chronic liver disease other than NAFLD (such as – but not restricted to

  • alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, etc.); 2. Patients with significantly impaired liver function: ALT or AST ≥ 2 times upper limit of normal; 3. HBsAg (+) and/or HCV-Ab (+); 4. Patients with type 1 diabetes mellitus or gestational diabetes or special type diabetes, and patients with BMI < 22 Kg/m2; 5. Course of diabetes more than 1 years; 6. Diabetics patients who have taken or are taking oral glucose-lowering drugs or insulin; 7. Diabetics patients with a HbA1c > 7.5% on initial visit; 8. Patients with severe diabetes complications (diabetes ketoacidosis, diabetes coma or with symptomatic of diabetes coma; dysfunction of nerve, retinopathy, dysfunction of kidney); 9. Patients with serum creatinine ≥ 1.5 mg/dL (133 umol/L); 10. Patients with a history of clinically significant heart disease (myocardial infarct, heart failure, and or severe cardiac rhythm); 11. Complicating severe infection, within 6 months after operation, severe trauma; 12. Patients with excess alcohol consumption≥140g/week(male); ≥ 70g/week(female); 13. Patients have participated other clinical trials within 24 weeks; 14. Patients with a history of drug allergy to TZDs and berberine; 15. Patients wth gestation or possible gestation or lactation, or males or females who expecting gestation during clinical trial; 16. Mental diseases patients; 17. Those who refuse to sign informed consent; 18. Any other conditions, which, in the opinion of the investigators would impede competence or compliance or possibility of hindering completion of the study; 19. Patients with serum triglyceride ≥ 5.0 mmol/L; 20. Patients with thyroid disease, including hyperthyroidism or hypothyroidism.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xin Gao
  • Collaborator
    • Shanghai Jiao Tong University School of Medicine
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Xin Gao, MD. and Professor, Vice-President of Zhongshan Hospital, Director of Department of Endocrinology & Metabolism of Zhongshan Hospital Fudan University – Fudan University
  • Overall Official(s)
    • Xin GAO, MD, Principal Investigator, Fudan University

References

Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005 Jul;42(1):44-52. doi: 10.1002/hep.20734.

Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005 Sep;43(3):508-14. doi: 10.1016/j.jhep.2005.02.042.

Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9. doi: 10.1210/jc.2004-0190.

Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):182-8. doi: 10.1161/01.ATV.0000195790.24531.4f. Epub 2005 Nov 10.

Shadid S, Stehouwer CD, Jensen MD. Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab. 2006 Sep;91(9):3418-25. doi: 10.1210/jc.2006-0015. Epub 2006 Jun 27.

Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K, Yoneda K, Takahashi H, Saito S, Iwasaki T, Yamamoto S, Tsutsumi S, Aburatani H, Wada K, Hotta K, Nakajima A. Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci. 2007 Oct;105(2):151-6. doi: 10.1254/jphs.fm0070063. Epub 2007 Oct 6.

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec;10(12):1344-51. doi: 10.1038/nm1135. Epub 2004 Nov 7.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.